Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Prostate Cancer and Prostatic Diseases
|
January 15, 2020
GLUT1 expression in high-risk prostate cancer: correlation with <sup>18</sup>F-FDG-PET/CT and clinical outcome
Salma Meziou, Cassandra Ringuette Goulet, Hélène Hovington, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 18, 2023
A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
Damian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
March 22, 2021
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy
Samuel Otis-Chapados, Cassandra Ringuette Goulet, Gabriel Dubois, et al.
BJU International
|
October 21, 2021
The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol
Frédéric Pouliot, Jean-Mathieu Beauregard, Fred Saad, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
July 15, 2025
The tumour sink effect on <sup>68</sup>Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
Atefeh Zamanian, Étienne Rousseau, François-Alexandre Buteau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 22, 2025
Can <sup>177</sup>Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
Azadeh Akhavanallaf, Zhonglin Lu, Avery B Peterson, et al.
Journal of Neurology
|
February 1, 2022
Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1
Robert Jr Laforce, Caroline Dallaire-Théroux, Annie M Racine, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 26, 2024
Dosimetry and pharmacokinetics of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Seval Beykan Schürrle, Uta Eberlein, Catherine Ansquer, et al.
Operative Neurosurgery (Hagerstown, Md.)
|
March 20, 2018
Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma
Julia R Schneider, Deborah R Shatzkes, Stephen C Scharf, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
February 17, 2026
Trajectory timelines and treatment efficacy of <sup>177</sup>Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center
Frédéric Pouliot, Michele Lodde, Marjorie Besançon, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Prostate Cancer and Prostatic Diseases
|
January 15, 2020
GLUT1 expression in high-risk prostate cancer: correlation with <sup>18</sup>F-FDG-PET/CT and clinical outcome
Salma Meziou, Cassandra Ringuette Goulet, Hélène Hovington, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 18, 2023
A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
Damian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
March 22, 2021
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy
Samuel Otis-Chapados, Cassandra Ringuette Goulet, Gabriel Dubois, et al.
BJU International
|
October 21, 2021
The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol
Frédéric Pouliot, Jean-Mathieu Beauregard, Fred Saad, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
July 15, 2025
The tumour sink effect on <sup>68</sup>Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
Atefeh Zamanian, Étienne Rousseau, François-Alexandre Buteau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 22, 2025
Can <sup>177</sup>Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
Azadeh Akhavanallaf, Zhonglin Lu, Avery B Peterson, et al.
Journal of Neurology
|
February 1, 2022
Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1
Robert Jr Laforce, Caroline Dallaire-Théroux, Annie M Racine, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 26, 2024
Dosimetry and pharmacokinetics of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Seval Beykan Schürrle, Uta Eberlein, Catherine Ansquer, et al.
Operative Neurosurgery (Hagerstown, Md.)
|
March 20, 2018
Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma
Julia R Schneider, Deborah R Shatzkes, Stephen C Scharf, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
February 17, 2026
Trajectory timelines and treatment efficacy of <sup>177</sup>Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center
Frédéric Pouliot, Michele Lodde, Marjorie Besançon, et al.
Page
of 7